Hello, Cleveland Biolabs! Here comes a merger with Cytocom
Privately held Cytocom Inc. and Cleveland Biolabs Inc. will merge in an all-stock transaction, with Cytocom shareholders taking the majority position.
The transaction, which must be approved by Cleveland Biolabs’ shareholders, is expected to close in the first quarter of 2021. The combined company, formed to pursue therapies to modulate the immune system for treating oncology, infectious disease and inflammation and autoimmune-mediated conditions, will beknown as Cytocom.
The full article can be accessed here
Contact
Cytocom Media:
Tiberend Strategic Advisors, Inc.
Johanna Bennett
212-375-2686
jbennett@tiberend.com
Cytocom Investors:
Maureen McEnroe, CFA/Miriam Weber Miller
212-375-2664/212-375-2694
Cleveland BioLabs:
Cleveland BioLabs, Inc.
(716) 849-6810 ext. 101
investor.relations@cbiolabs.com